Results: FormFactor, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Shareholders will be ecstatic, with their stake up 28% over the past week following FormFactor, Inc.'s (NASDAQ:FORM) latest annual results. It looks like a credible result overall - although revenues of US$785m were in line with what the analysts predicted, FormFactor surprised by delivering a statutory profit of US$0.69 per share, a notable 11% above expectations. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

earnings-and-revenue-growth
NasdaqGS:FORM Earnings and Revenue Growth February 7th 2026

Taking into account the latest results, the most recent consensus for FormFactor from ten analysts is for revenues of US$912.6m in 2026. If met, it would imply a solid 16% increase on its revenue over the past 12 months. Per-share earnings are expected to surge 94% to US$1.36. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$861.7m and earnings per share (EPS) of US$1.09 in 2026. There's been a pretty noticeable increase in sentiment, with the analysts upgrading revenues and making a great increase in earnings per share in particular.

See our latest analysis for FormFactor

With these upgrades, we're not surprised to see that the analysts have lifted their price target 29% to US$84.11per share. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values FormFactor at US$100.00 per share, while the most bearish prices it at US$64.00. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await FormFactor shareholders.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's clear from the latest estimates that FormFactor's rate of growth is expected to accelerate meaningfully, with the forecast 16% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 0.2% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to see revenue growth of 20% annually. So it's clear that despite the acceleration in growth, FormFactor is expected to grow meaningfully slower than the industry average.

Advertisement

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards FormFactor following these results. Fortunately, they also upgraded their revenue estimates, although our data indicates it is expected to perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple FormFactor analysts - going out to 2027, and you can see them free on our platform here.

We also provide an overview of the FormFactor Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:FORM

FormFactor

Designs, manufactures, and sells probe cards, analytical probes, probe stations, thermal systems, cryogenic systems, and related services in the United States, South Korea, Taiwan, China, Japan, Singapore, Europe, Malaysia, and internationally.

Flawless balance sheet with reasonable growth potential.

Advertisement

Weekly Picks

LO
Lou_Basenese
VTIX logo
Lou_Basenese on Virtuix Holdings ·

From a “Shark Tank” Snub to an Air Force “Yes”: Why Virtuix at $3.50 May Be the Market’s Most Mispriced AI Story

Fair Value:US$7.551.2% undervalued
5 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75034.9% undervalued
25 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
TR
tripledub
INTU logo
tripledub on Intuit ·

A Wonderful Business at a Not-So-Wonderful Price

Fair Value:US$56053.9% undervalued
54 users have followed this narrative
2 users have commented on this narrative
28 users have liked this narrative
TA
Talos
HYFT logo
Talos on MindWalk Holdings ·

The Asymmetric TechBio Play: MindWalk Holdings and the Valuation Disconnect

Fair Value:US$8.2782.0% undervalued
19 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative

Updated Narratives

AN
AnimalDoctorKwon
RCKT logo
AnimalDoctorKwon on Rocket Pharmaceuticals ·

The Structural Disconnect Between Market Valuation and Operational Maturity

Fair Value:US$1066.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
AKBA logo
AnimalDoctorKwon on Akebia Therapeutics ·

Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio

Fair Value:US$77.2998.6% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
MBIO logo
AnimalDoctorKwon on Mustang Bio ·

A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???

Fair Value:US$1.861.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7444.6% undervalued
67 users have followed this narrative
0 users have commented on this narrative
16 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$319.9638.3% undervalued
61 users have followed this narrative
9 users have commented on this narrative
18 users have liked this narrative
HE
HedgeY
ASTS logo
HedgeY on AST SpaceMobile ·

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets

Fair Value:US$17057.1% undervalued
51 users have followed this narrative
0 users have commented on this narrative
13 users have liked this narrative